New targeted pill shows promise for rare bile duct cancer in Real-World study
NCT ID NCT06607302
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is tracking 100 adults with a rare and aggressive bile duct cancer that has a specific IDH1 gene mutation. Participants will take the targeted drug ivosidenib, which was recently approved in Europe. Researchers will monitor how long the cancer stays under control, overall survival, and quality of life in everyday medical practice.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ivosidenib (a targeted cancer pill)
What this could lead to
If successful, this study could confirm that ivosidenib is a safe and effective treatment option for people with this rare bile duct cancer, potentially improving survival and quality of life.
What could go wrong
This is an observational study, not a controlled trial, so results may be less definitive. The cancer is aggressive, and the drug may not work for everyone or may cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Caritas Krankenhaus Bad Mergentheim
RECRUITINGBad Mergentheim, Germany
Contact
-
Gemeinschaftspraxis Hämatologie - Onkologie
RECRUITINGDresden, Germany
Contact
-
Gemeinschaftspraxis für Internistische Onkologie und Hämatologie
RECRUITINGRheine, Germany
Contact
-
Hämatologisch-Onkologische Schwerpunktpraxis in Bad Liebenwerda
RECRUITINGBad Liebenwerda, Germany
Contact
-
Medizinisches Versorgungszentrum Mönchengladbach
RECRUITINGMönchengladbach, Germany
Contact
-
Onkologie Hannover
RECRUITINGHanover, Germany
Contact
-
Onkologie Hof
RECRUITINGHof, Germany
Contact
-
Onkologisches Versorgungszentrum Berlin MVZ
RECRUITINGBerlin, Germany
Contact
-
Onkozentrum Dresden
RECRUITINGDresden, Germany
Contact
-
RoMed Klinikum Rosenheim, Hämatologie und Onkologie
RECRUITINGRosenheim, Germany
Contact
-
TUM Klinikum Rechts der Isar, Klinik und Poliklinik für Innere Medizin II
RECRUITINGMünchen, Germany
Contact
-
Universitätsklinikum Essen, Innere Klinik (Tumorforschung)
RECRUITINGEssen, Germany
Contact
-
ze:roPRAXEN MVZ für Innere Medizin
RECRUITINGWeinheim, Germany
Contact